ALXO
ALX ONCOLOGY HOLDINGS INC
Key Financials
Net Income
$-101695000
↑ 24.6%
Revenue
$0
NaN%
Operating Income
$-104021000
↑ 27.0%
Total Assets
$59.0M
↓ 60.0%
Cash & Equivalents
$16.4M
↓ 6.8%
Total Liabilities
$33.1M
↓ 3.2%
Long-term Debt
$10.2M
↓ 4.1%
Shareholders' Equity
$26.0M
↓ 77.1%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/30/2026 | View on SEC |
| 8-K | 6/26/2026 | View on SEC |
| 8-K | 6/11/2026 | View on SEC |
| SCHEDULE 13D/A | 5/27/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| SCHEDULE 13G/A | 5/15/2026 | View on SEC |
| 10-Q | 5/8/2026 | View on SEC |
| 8-K | 5/8/2026 | View on SEC |
| SCHEDULE 13G/A | 4/28/2026 | View on SEC |
| ARS | 4/20/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | ALXO |
| Company Name | ALX ONCOLOGY HOLDINGS INC |
| CIK | 1810182 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 650-466-7125 |